ArticleJournal of thoracic disease2018

A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification.

Hanting Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.